JP Morgan Chase
IBRX icon

JP Morgan Chase’s ImmunityBio IBRX Stock Holding History

JP Morgan Chase’s Portfolio IBRX Stock Details IBRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-5,200
Closed -$34.6K – 7895
2026
Q1 		$34.6K Buy
+5,200
New +$35.6K ﹤0.01% 6344
2017
Q3 		– Sell
-200,000
Closed -$1.52M – 5052
2017
Q2 		$1.52M Buy
+200,000
New +$864K ﹤0.01% 3207

Other funds holding IBRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

JP Morgan Chase's IBRX Position: Q2 2026 in Review

JP Morgan Chase reduced its ImmunityBio (IBRX) stake by 2.6% in Q2 2026, selling an estimated $298K and leaving 1,450,180 shares worth $12.9M. The position accounts for ﹤0.01% of the portfolio, ranked #2591.

JP Morgan Chase first reported a position in IBRX in Q3 2015 and has held it in 44 quarters since. The position peaked at $12.9M in Q1 2021. 405 funds tracked by Wall St. Rank hold IBRX as of Q2 2026.

  • JP Morgan Chase held 1,450,180 shares of ImmunityBio worth $12.9M as of Q2 2026.
  • JP Morgan Chase sold 39,329 ImmunityBio shares in Q2 2026, an estimated $298K.
  • ImmunityBio made up ﹤0.01% of JP Morgan Chase's portfolio in Q2 2026, its #2591 holding.
  • JP Morgan Chase first reported a position in ImmunityBio in Q3 2015 and has held it in 44 quarters since.
  • JP Morgan Chase's ImmunityBio position peaked at $12.9M in Q1 2021.
  • 405 funds tracked by Wall St. Rank held ImmunityBio as of Q2 2026.

Based on JP Morgan Chase's 13F filing for Q2 2026, filed 12 Aug 2026.